Hepatitis B Vaccine Helps Prevent Liver Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 2
Volume 9
Issue 2

PHILADELPHIA—SmithKline Beecham has announced that labeling for Engerix-B (hepatitis B vaccine recombinant) now includes a statement recognizing the hepatitis B vaccine as “the first anti-cancer vaccine because it can prevent primary liver cancer. A clear link has been demonstrated between chronic hepatitis B infection and the occurrence of hepatocellular carcinoma.”

PHILADELPHIA—SmithKline Beecham has announced that labeling for Engerix-B (hepatitis B vaccine recombinant) now includes a statement recognizing the hepatitis B vaccine as “the first anti-cancer vaccine because it can prevent primary liver cancer. A clear link has been demonstrated between chronic hepatitis B infection and the occurrence of hepatocellular carcinoma.”

The labeling reflects the fact that the FDA has recognized the CDC’s description of hepatitis B vaccines as preventing hepatitis B infections that can lead to primary liver cancer. In the United States, about 15% of the reported cases of primary liver cancer develop from chronic hepatitis B infections.

Articles in this issue
Neoadjuvant Docetaxel Increases Response Rate in Large Breast Tumors
Faslodex, a Pure Antiestrogen, Shows Antitumor Activity
Consider Node Dissection, Adjuvant Therapy in Elderly Breast Cancer Patients
Tumor-Associated Proteases Predict Outcome in Node-Negative Patients
Herceptin Plus Vinorelbine a Promising Combination in Advanced Breast Cancer
Adjuvant Therapy Improves Relapse-Free Survival With Small, Node-Negative Tumors
Small Risk of Breast Cancer Death After Invasive Recurrence in DCIS Patients
Paclitaxel/Herceptin Effective in Metastatic Breast Cancer
Conservative Surgery Alone Not Sufficient to Prevent Recurrence
Surgical Margin Width Is a Reasonable Surrogate for Van Nuys Prognostic Index
Intensive Sequential Adjuvant Chemo for High-Risk Breast Cancer Patients
Anastrozole as Effective as Tamoxifen as First-Line Therapy of Advanced Breast Cancer
Sentinel Node Biopsy: Reasons for Failure
AT Superior to FAC in Metastatic Breast Cancer
New SERM Promising in Advanced Breast Cancer
Recent Videos
Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
A panel of 5 experts on multiple myeloma
Related Content
A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.

Uterine Transposition Surgery Improves QOL Through Fertility Preservation

Ariana Pelosci
October 8th 2024
Article

A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Forming Connections and Making a Difference in the Brain Cancer Field

Yoshie Umemura, MD
October 7th 2024
Podcast

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Results from KEYNOTE-671 show an improvement in OS when a neoadjuvant/adjuvant regimen of pembrolizumab was used to treat patients with NSCLC.

Neoadjuvant/Adjuvant Pembrolizumab Combo Improves OS in NSCLC

Ariana Pelosci
October 8th 2024
Article

Results from KEYNOTE-671 show an improvement in OS when a neoadjuvant/adjuvant regimen of pembrolizumab was used to treat patients with NSCLC.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Treatment with durcabtagene autoleucel meets the primary end point of a phase 2 study in relapsed/refractory multiple myeloma.

Durcabtagene Autoleucel Yields Responses in Relapsed/Refractory Myeloma

Sabrina Serani
October 7th 2024
Article

Treatment with durcabtagene autoleucel meets the primary end point of a phase 2 study in relapsed/refractory multiple myeloma.

Data from the LUMINOSITY trial support the application for telisotuzumab vedotin in nonsquamous NSCLC harboring c-Met protein overexpression.

BLA Submitted for Teliso-V in Advanced EGFR Wild-type NSCLC

Russ Conroy
October 7th 2024
Article

Data from the LUMINOSITY trial support the application for telisotuzumab vedotin in nonsquamous NSCLC harboring c-Met protein overexpression.